A high-throughput strategy targeting MDM2 is presented as a potential way to overcome radiation resistance in uveal melanoma, a cancer where durable control remains difficult. The approach focuses on identifying therapeutically relevant vulnerabilities in models that resist radiation, aiming to re-sensitize tumors to standard treatment. By shifting discovery toward scalable screening and mechanistic readouts, the work reflects how teams are trying to accelerate the path from resistance biology to testable combination regimens.